The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

If a new experiment pans out, Medicaid and Medicare could begin covering the costly weight-loss drugs that price out many ...

How much Medicare spent on the drugs Among the 10 drugs listed, Medicare Part D spent the most on Ozempic, Rybelsus and Wegovy, at $14.43 billion, according to a CMS fact sheet on Friday.

Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

Medicare covers Ozempic for Type 2 diabetes Medicare prescription drug plans might cover Ozempic, but only to treat diabetes. In 2021, Medicare spent over $2.6 billion to cover Ozempic prescriptions.